The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus

BZ Group
  • 5.0 (1)
  • LIFE SCIENCES
  • UPDATED DAILY

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Weekend Edition every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created

  1. 22H AGO

    May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off

    Myqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3 siRNA for up to $1B, and the Supreme Court keeps mifepristone in play. Visit us at www.thepharamcloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Cytokinetics,Myqorzo, aficamten, hypertrophic cardiomyopathy, HCM, ACACIA-HCM, Pfizer,Trillium Therapeutics, CD47, Madrigal, Arrowhead, MASH, PNPLA3, Rezdiffra,mifepristone, Supreme Court, Auvelity, Axsome, Viridian, Tepezza, Intercept,BioNTech, Jakafi XR, Incyte, Leqembi, Sanofi, Passage Bio, Gilead, Arcellx,Novartis, J&J, Amgen

    10 min

  2. 1D AGO

    May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval

    Supreme Court grants emergency stay restoring mifepristone access — and the ruling's implications hit every drugmaker's risk model. Plus: Arvinas/Pfizer's vepdegestrant becomes the first PROTAC approved by the FDA, UCB acquires Candid Therapeutics for $2.2B in autoimmune bispecifics, and Cytokinetics' pivotal HCM readout lands tomorrow. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, mifepristone, Supreme Court, PROTAC, vepdegestrant, Veppanu, Arvinas, Pfizer, UCB, Candid Therapeutics, bispecific antibodies, autoimmune, Teva, Emalex, ecopipam, Tourette syndrome, Ligand, XOMA, royalty, Incyte, Jakafi XR, ruxolitinib, Axsome, Auvelity, Alzheimer's agitation, Celcuity, gedatolisib, breast cancer, Cytokinetics, aficamten, HCM, Samsung Biologics, Windward Bio, Amgen, Novartis, oral GLP-1, Foundayo, Wegovy, AbbVie, Regeneron

    10 min

  3. 2D AGO

    May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos

    UCB drops $2B upfront for Candid Therapeutics' autoimmune T-cell engager cizutamig — their second billion-dollar deal in three weeks. FDA proposes withdrawing Amgen's Tavneos over data manipulation allegations. Pfizer/Arvinas' Veppanubecomes the first approved PROTAC degrader Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, UCB, Candid vTherapeutics, cizutamig, autoimmune, T-cell engager, BCMA, Amgen, Tavneos, avacopan, FDA withdrawal, Pfizer, Arvinas, Veppanu, vepdegestrant, PROTAC, Teva, Emalex, ecopipam, Tourette syndrome, Summit Therapeutics, ivonescimab, Harmoni-3, Axsome, Auvelity, Alzheimer's, argenx, Vyvgart, Enhertu, Leqembi, ASCO, Moderna, M&A, biotech IPO, Lilly, AstraZeneca, Gilead, Biogen

    13 min

  4. 2D AGO

    May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1

    FDA clears Veppanu, the first protein degrader to reachmarket — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgency drives a mega year. Plus: Truqap wins 7-1 ODAC vote in prostate cancer, Auvelity expands into Alzheimer's agitation, and Summit's ivonescimab stumbles before ASCO. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Veppanu,vepdegestrant, Arvinas, Pfizer, PROTAC, protein degrader, breast cancer, FDA approval, AstraZeneca, Truqap, capivasertib, ODAC, prostate cancer, SummitTherapeutics, ivonescimab, Esperion, ArchiMed, Teva, Emalex, ecopipam, Tourette syndrome, Axsome, Auvelity, Alzheimer's agitation, Moderna, Amgen, obesity,Tavneos, Chiesi, KalVista, Ligand, XOMA, Avalyn, Elrexfio, Lilly, Foundayo, Samsung Biologics, UniQure, Huntington's, pharma M&A, patent cliff, Merck, Gilead

    10 min

  5. APR 29

    Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal

    Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli Lilly, Ajax Therapeutics, JAKinhibitor, myelofibrosis, Amgen, Tavneos, ChemoCentryx, data manipulation, Intellia Therapeutics, CRISPR, gene editing, BridgeBio, Vyndamax, Pfizer, Boehringer Ingelheim, survodutide, obesity, AstraZeneca, Breztri, asthma,Incyte, vitiligo, Oruka, psoriasis, Veradermics, Sanofi, tolebrutinib, Lilly

    10 min

  6. APR 28

    Apr 27, 2026 | Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon

    Sun Pharma just wrote an eleven-point-seven-five billiondollar check to acquire Organon — the largest outbound pharma acquisition in Indian history, according to Reuters. And Intellia's in vivo CRISPR therapyjust delivered the first Phase 3 win for gene editing inside the body. Big Monday. Let's get into it. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Eli Lilly, Lilly, AstraZeneca, Merck, AbbVie, Regeneron

    11 min

  7. APR 25

    Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B

    Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly, Novo Nordisk, Wegovy, oral GLP-1, obesity, Inhibrx, INBRX-106, Merck, Merck KGaA, Ono Pharmaceutical, oncology, tolebrutinib, Cenrifki, Sanofi, multiple sclerosis, SPMS, Regeneron, Otarmeni, gene therapy, hearing loss, Compass Pathways, Usona Institute, Transcend Therapeutics, psychedelics, psilocybin, AbbVie, CRL, Novartis, Pluvicto, Kelonia Therapeutics, Intellia, CRISPR, Roche, Moderna, Daiichi Sankyo, Avalyn Pharma, Pfizer, Lilly

    10 min

  8. APR 24

    Apr 23, 2026 | Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss

    FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, Otarmeni, gene therapy, hearing loss, FDA approval, MFN pricing, White House, Roche, giredestrant, breast cancer, Novo Nordisk, oral semaglutide, Foundayo, orforglipron, AbbVie, Durham, manufacturing, Rigel, Eli Lilly, RIPK1, Grace Therapeutics, GTX-104, nimodipine, Sanofi, Dupixent, Novartis, radioligand therapy, GE HealthCare, LUMINA, Tempero, Amgen, Inovio, Lilly

    9 min
See All (54)

About

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Weekend Edition every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created

Information

You Might Also Like